ArticleBioorganic & medicinal chemistry letters2013
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
Article in Bioorganic & medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- A Review of Antibacterial Candidates with New Modes of Action.ACS infectious diseases · 2024Review
- Atroposelective Total Synthesis of Darobactin A.Journal of the American Chemical Society · 2022Article
- Carrier Protein-Free Enzymatic Biaryl Coupling in Arylomycin A2 Assembly and Structure of the Cytochrome P450 AryC.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Emerging peptide antibiotics with therapeutic potential.Medicine in drug discovery · 2021Review
- Development and Research Progress of Anti-Drug Resistant Bacteria Drugs.Infection and drug resistance · 2021Review
- The quest for supernatural products: the impact of total synthesis in complex natural products medicinal chemistry.Natural product reports · 2020Review
- Tackling Antibiotic Resistance with Compounds of Natural Origin: A Comprehensive Review.Biomedicines · 2020Review
- Article
- Article
- Fixing the Unfixable: The Art of Optimizing Natural Products for Human Medicine.Journal of medicinal chemistry · 2019Review
- A positive positive to negative.Nature chemistry · 2018Article
- Article
- Scalable Access to Arylomycins via C-H Functionalization Logic.Journal of the American Chemical Society · 2018Article
- Polishing the tarnished silver bullet: the quest for new antibiotics.Essays in biochemistry · 2017Review
- Not just an antibiotic target: Exploring the role of type I signal peptidase in bacterial virulence.Bioorganic & medicinal chemistry · 2016Article
- Article
- Origins of Yersinia pestis sensitivity to the arylomycin antibiotics and the inhibition of type I signal peptidase.Antimicrobial agents and chemotherapy · 2015Article
- A putative cro-like repressor contributes to arylomycin resistance in Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
New antibiotics are needed, and one source may be 'latent' antibiotics, natural products whose once broad-spectrum activity is currently limited by the evolution of resistance in nature. We have identified a potential class of latent antibiotics, the arylomycins, which are lipopeptides with a C-terminal macrocycle that target signal peptidase and whose spectrum is limited by a resistance-conferring mutation in many bacteria. Herein, we report the synthesis and evaluation of several arylomycin derivatives, and demonstrate that both C-terminal homologation with a glycyl aldehyde and addition of a positive charge to the macrocycle increase the activity and spectrum of the arylomycin scaffold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.